The ace inhibitors market has grown steadily in recent years. It will grow from $6.9 billion in 2023 to $7.24 billion in 2024 at a compound annual growth rate (CAGR) of 4.9%. The observed growth in the historical period can be attributed to various factors. These include the heightened incidence of cardiovascular diseases, a growing aging population, the clinical effectiveness, and safety profile of medical interventions, the prevalence of diabetes, and the influence of regulatory endorsements and guidelines.
The ace inhibitors market is expected to see strong growth in the next few years. It will grow to $9 billion in 2028 at a compound annual growth rate (CAGR) of 5.6%. The expected growth in the forecast period is linked to several factors, notably the escalating global burden of cardiovascular diseases, the broadening scope of hypertension treatment guidelines, advancements in combination therapies, an increased focus on heart failure management, and improved awareness and access to healthcare. Key trends anticipated in the forecast period encompass a heightened emphasis on kidney protection, a preference for renin-angiotensin system inhibitors, challenges associated with generic competition and pricing pressures, a shift toward patient-centric approaches in healthcare, and the influence of regulatory updates and safety considerations.
The escalating prevalence of hypertension disorders is anticipated to play a pivotal role in driving the growth of the ACE inhibitors market. Hypertension, or high blood pressure, is characterized by elevated pressure within the blood vessels. ACE inhibitors, belonging to the category of angiotensin-converting enzyme inhibitors, represent a group of medications employed for the treatment and management of hypertension. These medications operate by relaxing blood vessels, leading to a reduction in blood pressure and an enhancement in blood flow. As of March 2023, the World Health Organization reported that an estimated 1.28 billion adults aged 30 to 79 worldwide were affected by hypertension, with two-thirds of these individuals residing in low- and middle-income nations. Over the past three decades, there has been a substantial increase of 650 million people aged 30 to 79 with hypertension. Alarmingly, around 46% of adults with hypertension are unaware of their condition due to a lack of diagnosis. This surge in hypertension cases stands as a significant factor propelling the growth of the ACE inhibitors market.
The rising incidence of cardiac disorders is another critical factor expected to contribute to the expansion of the ACE inhibitors market. Cardiac disorders encompass a range of medical conditions affecting the heart or blood vessels, including coronary artery disease, heart failure, and arrhythmias. ACE inhibitors play a crucial role in managing cardiac disorders by inhibiting the angiotensin-converting enzyme, resulting in reduced vasoconstriction, sodium retention, and aldosterone secretion, ultimately improving cardiac function. For instance, in May 2023, the Centers for Disease Control and Prevention reported that coronary artery disease (CAD) was responsible for 375,476 deaths in 2021, with approximately 1 in 20 adults aged 20 and older being affected by CAD. Notably, about 2 in 10 deaths from CAD occurred in adults less than 65 years old. The increasing incidence of cardiac disorders is thus a substantial driver behind the growth of the ACE inhibitors market.
A notable trend with a strong emphasis on product innovations, as major companies strategically develop novel products to strengthen their market positions and gain a competitive advantage. For instance, in February 2023, Travere Therapeutics, a US-based biopharmaceutical company, achieved FDA approval for FILSPARI (sparsentan). This groundbreaking non-immunosuppressive therapy is intended for use in patients with IgA nephropathy (IgAN). FILSPARI represents a significant advancement as the only approved non-immunosuppressive therapy. It is an oral medication designed for once-daily use by adults with primary IgAN who are at risk of rapid disease progression, typically presenting with a UPCR of less than 1.5 g/g and proteinuria. This approval marks a noteworthy milestone in treatment options for IgAN, supplementing traditional approaches involving systemic glucocorticoids, angiotensin-converting enzyme (ACE) inhibitors, and antihypertensive medications, including angiotensin-receptor blockers (ARBs).
Major players in the ACE inhibitors market are further intensifying their efforts to introduce innovative drugs, as illustrated by the launch of a generic version of Capoten. Capoten is an ACE inhibitor containing the active ingredient captopril. In November 2021, Camber Pharmaceuticals Inc., a US-based pharmaceutical company, introduced the generic version known as Captopril. This medication is prescribed for conditions such as hypertension, congestive heart failure, kidney problems caused by diabetes, and to improve survival after a heart attack. Captopril is available in various dosage strengths (12.5 mg, 25 mg, 50 mg, and 100 mg) and is packaged in 100-count bottles.
In January 2023, AstraZeneca, a UK-based pharmaceutical company, made a significant acquisition by purchasing CinCor Pharma for $1.3 billion. This strategic move positions AstraZeneca to expand its product line of aldosterone synthase inhibitors (ASI), particularly for blood pressure lowering in the treatment of resistant hypertension. CinCor Pharma, a US-based clinical-stage biopharmaceutical company, specializes in developing novel treatments for resistant and uncontrolled hypertension, as well as chronic kidney disease. This acquisition aligns with AstraZeneca's overarching goal of diversifying its portfolio and addressing critical medical needs in the cardiovascular therapeutic area.
Major companies operating in the ace inhibitors market report are Pfizer Inc.,Novartis AG,Johnson & Johnson Private Limited, Merck KGaA,Sanofi S.A.,Bayer AG,United Therapeutics Corporation,Teva Pharmaceutical Industries Ltd.,Bristol-Myers Squibb Co.,Takeda Pharmaceuticals Company,Daiichi Sankyo Company Ltd.,UCB Schwarz Pharma Inc.,Solvay Pharmaceuticals B.V.,Endo International plc,Otto Brandes GmbH,Sun Pharmaceutical Industries Ltd.,Boehringer Ingelheim,Bausch Health Companies Inc.,Dr. Reddy's Laboratories,Abbott Laboratories,Eli Lilly and Company,Cipla Limited, GlaxoSmithKline plc,Cadila Healthcare Limited,AbbVie Inc., Mylan N.V., Sandoz Group AG,Accord Healthcare Ltd.,AstraZeneca plc,Lupin Limited,Macleods Pharmaceuticals Limited,Zydus lifescience Ltd.,Apotex Inc.
North America was the largest region in the ACE inhibitors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global ACE inhibitors market report during the forecast period. The regions covered in the ace inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ace inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The main categories of ACE inhibitors encompass sulfhydryl-containing agents, dicarboxylate-containing agents, and phosphonate-containing agents. Sulfhydryl-containing agents are compounds characterized by the presence of a sulfhydryl group (-SH) in their structure. Various drugs fall into this category, including ramipril, enalapril, benazepril, fosinopril, captopril, moexipril, and others. These medications are available in diverse dosage forms, such as oral tablets and oral solutions. They find application in the treatment of various conditions, including heart failure, chronic kidney disease, hypertension, diabetes, and heart attacks. These medications are utilized by a range of end-users, including hospitals and online drug stores.
The countries covered in the ACE inhibitors market consists of sales of various drugs including zofenopril, perindopril, enalapril, trandolapril. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The global ACE inhibitors market consists of sales of various drugs including zofenopril, perindopril, enalapril, trandolapril. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The ace inhibitors market is expected to see strong growth in the next few years. It will grow to $9 billion in 2028 at a compound annual growth rate (CAGR) of 5.6%. The expected growth in the forecast period is linked to several factors, notably the escalating global burden of cardiovascular diseases, the broadening scope of hypertension treatment guidelines, advancements in combination therapies, an increased focus on heart failure management, and improved awareness and access to healthcare. Key trends anticipated in the forecast period encompass a heightened emphasis on kidney protection, a preference for renin-angiotensin system inhibitors, challenges associated with generic competition and pricing pressures, a shift toward patient-centric approaches in healthcare, and the influence of regulatory updates and safety considerations.
The escalating prevalence of hypertension disorders is anticipated to play a pivotal role in driving the growth of the ACE inhibitors market. Hypertension, or high blood pressure, is characterized by elevated pressure within the blood vessels. ACE inhibitors, belonging to the category of angiotensin-converting enzyme inhibitors, represent a group of medications employed for the treatment and management of hypertension. These medications operate by relaxing blood vessels, leading to a reduction in blood pressure and an enhancement in blood flow. As of March 2023, the World Health Organization reported that an estimated 1.28 billion adults aged 30 to 79 worldwide were affected by hypertension, with two-thirds of these individuals residing in low- and middle-income nations. Over the past three decades, there has been a substantial increase of 650 million people aged 30 to 79 with hypertension. Alarmingly, around 46% of adults with hypertension are unaware of their condition due to a lack of diagnosis. This surge in hypertension cases stands as a significant factor propelling the growth of the ACE inhibitors market.
The rising incidence of cardiac disorders is another critical factor expected to contribute to the expansion of the ACE inhibitors market. Cardiac disorders encompass a range of medical conditions affecting the heart or blood vessels, including coronary artery disease, heart failure, and arrhythmias. ACE inhibitors play a crucial role in managing cardiac disorders by inhibiting the angiotensin-converting enzyme, resulting in reduced vasoconstriction, sodium retention, and aldosterone secretion, ultimately improving cardiac function. For instance, in May 2023, the Centers for Disease Control and Prevention reported that coronary artery disease (CAD) was responsible for 375,476 deaths in 2021, with approximately 1 in 20 adults aged 20 and older being affected by CAD. Notably, about 2 in 10 deaths from CAD occurred in adults less than 65 years old. The increasing incidence of cardiac disorders is thus a substantial driver behind the growth of the ACE inhibitors market.
A notable trend with a strong emphasis on product innovations, as major companies strategically develop novel products to strengthen their market positions and gain a competitive advantage. For instance, in February 2023, Travere Therapeutics, a US-based biopharmaceutical company, achieved FDA approval for FILSPARI (sparsentan). This groundbreaking non-immunosuppressive therapy is intended for use in patients with IgA nephropathy (IgAN). FILSPARI represents a significant advancement as the only approved non-immunosuppressive therapy. It is an oral medication designed for once-daily use by adults with primary IgAN who are at risk of rapid disease progression, typically presenting with a UPCR of less than 1.5 g/g and proteinuria. This approval marks a noteworthy milestone in treatment options for IgAN, supplementing traditional approaches involving systemic glucocorticoids, angiotensin-converting enzyme (ACE) inhibitors, and antihypertensive medications, including angiotensin-receptor blockers (ARBs).
Major players in the ACE inhibitors market are further intensifying their efforts to introduce innovative drugs, as illustrated by the launch of a generic version of Capoten. Capoten is an ACE inhibitor containing the active ingredient captopril. In November 2021, Camber Pharmaceuticals Inc., a US-based pharmaceutical company, introduced the generic version known as Captopril. This medication is prescribed for conditions such as hypertension, congestive heart failure, kidney problems caused by diabetes, and to improve survival after a heart attack. Captopril is available in various dosage strengths (12.5 mg, 25 mg, 50 mg, and 100 mg) and is packaged in 100-count bottles.
In January 2023, AstraZeneca, a UK-based pharmaceutical company, made a significant acquisition by purchasing CinCor Pharma for $1.3 billion. This strategic move positions AstraZeneca to expand its product line of aldosterone synthase inhibitors (ASI), particularly for blood pressure lowering in the treatment of resistant hypertension. CinCor Pharma, a US-based clinical-stage biopharmaceutical company, specializes in developing novel treatments for resistant and uncontrolled hypertension, as well as chronic kidney disease. This acquisition aligns with AstraZeneca's overarching goal of diversifying its portfolio and addressing critical medical needs in the cardiovascular therapeutic area.
Major companies operating in the ace inhibitors market report are Pfizer Inc.,Novartis AG,Johnson & Johnson Private Limited, Merck KGaA,Sanofi S.A.,Bayer AG,United Therapeutics Corporation,Teva Pharmaceutical Industries Ltd.,Bristol-Myers Squibb Co.,Takeda Pharmaceuticals Company,Daiichi Sankyo Company Ltd.,UCB Schwarz Pharma Inc.,Solvay Pharmaceuticals B.V.,Endo International plc,Otto Brandes GmbH,Sun Pharmaceutical Industries Ltd.,Boehringer Ingelheim,Bausch Health Companies Inc.,Dr. Reddy's Laboratories,Abbott Laboratories,Eli Lilly and Company,Cipla Limited, GlaxoSmithKline plc,Cadila Healthcare Limited,AbbVie Inc., Mylan N.V., Sandoz Group AG,Accord Healthcare Ltd.,AstraZeneca plc,Lupin Limited,Macleods Pharmaceuticals Limited,Zydus lifescience Ltd.,Apotex Inc.
North America was the largest region in the ACE inhibitors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global ACE inhibitors market report during the forecast period. The regions covered in the ace inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ace inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The main categories of ACE inhibitors encompass sulfhydryl-containing agents, dicarboxylate-containing agents, and phosphonate-containing agents. Sulfhydryl-containing agents are compounds characterized by the presence of a sulfhydryl group (-SH) in their structure. Various drugs fall into this category, including ramipril, enalapril, benazepril, fosinopril, captopril, moexipril, and others. These medications are available in diverse dosage forms, such as oral tablets and oral solutions. They find application in the treatment of various conditions, including heart failure, chronic kidney disease, hypertension, diabetes, and heart attacks. These medications are utilized by a range of end-users, including hospitals and online drug stores.
The countries covered in the ACE inhibitors market consists of sales of various drugs including zofenopril, perindopril, enalapril, trandolapril. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The global ACE inhibitors market consists of sales of various drugs including zofenopril, perindopril, enalapril, trandolapril. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. ACE Inhibitors Market Characteristics3. ACE Inhibitors Market Trends and Strategies31. Global ACE Inhibitors Market Competitive Benchmarking32. Global ACE Inhibitors Market Competitive Dashboard33. Key Mergers and Acquisitions in the ACE Inhibitors Market
4. ACE Inhibitors Market - Macro Economic Scenario
5. Global ACE Inhibitors Market Size and Growth
6. ACE Inhibitors Market Segmentation
7. ACE Inhibitors Market Regional and Country Analysis
8. Asia-Pacific ACE Inhibitors Market
9. China ACE Inhibitors Market
10. India ACE Inhibitors Market
11. Japan ACE Inhibitors Market
12. Australia ACE Inhibitors Market
13. Indonesia ACE Inhibitors Market
14. South Korea ACE Inhibitors Market
15. Western Europe ACE Inhibitors Market
16. UK ACE Inhibitors Market
17. Germany ACE Inhibitors Market
18. France ACE Inhibitors Market
19. Italy ACE Inhibitors Market
20. Spain ACE Inhibitors Market
21. Eastern Europe ACE Inhibitors Market
22. Russia ACE Inhibitors Market
23. North America ACE Inhibitors Market
24. USA ACE Inhibitors Market
25. Canada ACE Inhibitors Market
26. South America ACE Inhibitors Market
27. Brazil ACE Inhibitors Market
28. Middle East ACE Inhibitors Market
29. Africa ACE Inhibitors Market
30. ACE Inhibitors Market Competitive Landscape and Company Profiles
34. ACE Inhibitors Market Future Outlook and Potential Analysis
35. Appendix
Executive Summary
This report provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on ace inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for ace inhibitors? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Sulfhydryl-containing Agents; Dicarboxylate-containing Agents; Phosphonate-containing Agents
2) By Drug: Ramipril; Enalapril; Benazepril; Fosinopril; Captopril; Moexipril; Other Drugs
3) By Dosage Form: Oral Tablets; Oral Solutions
4) By Application: Heart Failure; Chronic Kidney Disease; Hypertension; Diabetes; Heart Attack; Other Applications
5) By End-Users: Hospitals; Online Drug Stores; Other End-Users
Companies Mentioned: Pfizer Inc.; Novartis Gohonzon & Johnson Private Limited; Merck Gaisano S.A.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Pfizer Inc.
- Novartis AG
- Johnson & Johnson Private Limited
- Merck KGaA
- Sanofi S.A.
- Bayer AG
- United Therapeutics Corporation
- Teva Pharmaceutical Industries Ltd.
- Bristol-Myers Squibb Co.
- Takeda Pharmaceuticals Company
- Daiichi Sankyo Company Ltd.
- UCB Schwarz Pharma Inc.
- Solvay Pharmaceuticals B.V.
- Endo International plc
- Otto Brandes GmbH
- Sun Pharmaceutical Industries Ltd.
- Boehringer Ingelheim
- Bausch Health Companies Inc.
- Dr. Reddy's Laboratories
- Abbott Laboratories
- Eli Lilly and Company
- Cipla Limited
- GlaxoSmithKline plc
- Cadila Healthcare Limited
- AbbVie Inc.
- Mylan N.V.
- Sandoz Group AG
- Accord Healthcare Ltd.
- AstraZeneca plc
- Lupin Limited
- Macleods Pharmaceuticals Limited
- Zydus lifescience Ltd.
- Apotex Inc.
Methodology
LOADING...
